Credit Suisse’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Credit Suisse’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-467,964	Closed	-$9.79M	–	4360
2016 Q3	$9.79M	Buy	467,964 +442,159	+1,713%	+$5.09M	0.01%	1207
2016 Q2	$278K	Buy	25,805 +1,049	+4%	+$8.97K	﹤0.01%	3728
2016 Q1	$164K	Buy	+24,756	New	+$225K	﹤0.01%	3734
2015 Q4	–	Sell	-14,670	Closed	-$162K	–	4479
2015 Q3	$162K	Buy	+14,670	New	+$156K	﹤0.01%	3998

Credit Suisse's VTAE Position: Q4 2016 in Review

Credit Suisse sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 467,964 shares — an estimated $9.79M sold.

Credit Suisse first reported a position in VTAE in Q3 2015 and held it in 4 quarters. The position peaked at $9.79M in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

Credit Suisse reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
Credit Suisse sold 467,964 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $9.79M.
Credit Suisse first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q3 2015 and held it in 4 quarters.
Credit Suisse's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $9.79M in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on Credit Suisse's 13F filing for Q4 2016, filed 14 Feb 2017.